(2022)
Clinical, pathological, and molecular prognostic factors in patients with early-stage EGFR mutant NSCLC.
CLINICAL CANCER RESEARCH.
-,
-
(2022)
Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial.
JOURNAL OF THORACIC ONCOLOGY.
17,
7
(2022)
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
CANCER MEDICINE.
11,
13
(2022)
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small-cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
TRANSLATIONAL LUNG CANCER RESEARCH.
11,
7
(2022)
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
JOURNAL OF CLINICAL ONCOLOGY.
40,
17
(2022)
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
CLINICAL LUNG CANCER.
23,
4
(2022)
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS.
113,
2
(2022)
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
JOURNAL OF THORACIC ONCOLOGY.
17,
6
(2022)
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
CLINICAL LUNG CANCER.
23,
4
(2022)
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
CLINICAL LUNG CANCER.
23,
3
(2022)
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
EUROPEAN JOURNAL OF ENDOCRINOLOGY.
186,
6
(2022)
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.
FRONTIERS IN ONCOLOGY.
12,
(2022)
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
ONCOLOGY.
100,
4
(2022)
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.
INVESTIGATIONAL NEW DRUGS.
40,
2
(2022)
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
CURRENT ONCOLOGY.
29,
3
(2022)
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study.
ESMO OPEN.
7,
1
(2021)
Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system.
TRANSLATIONAL LUNG CANCER RESEARCH.
10,
10
(2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
JOURNAL OF CLINICAL ONCOLOGY.
-,
-
(2021)
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
JOURNAL OF THORACIC ONCOLOGY.
16,
8
(2021)
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer.
CLINICAL CANCER RESEARCH.
-,
-
단행본
(2003)
성장인자.
일조각.
단독
(2002)
두경부암의 항암화학요법.
일조각.
단독
(1998)
내과학.
고려의학.
공동
학술회의논문
(2017)
MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology..
J Thorac Oncol.
미국
(2016)
First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC..
J Thorac Oncol.
미국
(2010)
"Are Those Really the Same Stage?" - Persistent Dilemmas and Controversies of the Revised TNM Staging of Non-Small Cell Lung Cancer and Answers Based on Tertiary Hospital Experience.
Journal of Thoracic Oncology.
대한민국
(2010)
A Phase II Trial of Neoadjuvant Erlotinib (TARCEVA) Followed by Surgery for Selected Patients with Stage IIIA, N2-Positive Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
대한민국
(2010)
EpCAM in Lung Adenocarcinoma Proliferation and Progression.
Journal of Thoracic Oncology.
대한민국
(2010)
Genetic Polymorphisms in Folate Metabolic Pathway Cenes Correlate with Clinical Outcomes in Pemetrexed-Treated Advanced NSCLC Patients..
Journal of Thoracic Oncology.
대한민국
(2010)
Involved Field Radiation Therapy as a Salvage Treatment for Loco-Regional Recurrence after Complete Resection of Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
대한민국
(2010)
Outcomes of Surgical N2-Positive Non-Small Cell Lung Cancer Patients Based on Adjuvant Therapy Modality: Single Institute Retrospective Analysis.
Journal of Thoracic Oncology.
대한민국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Thoracic Oncology.
대한민국
(2010)
Quantification of Anti-Angiogenic Effect of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKLs) with Dynamic Contrast-Enhanced MR Imaging (DCE-MRI) in Patients with Non-Small Cell Lung Cancer (NSCLC) : Feasibility Study.
Journal of Thoracic Oncology.
대한민국
(2010)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Maintenance for Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Following 1st-Line Platinum-Doublet Chemotherapy.
Journal of Thoracic Oncology.
대한민국
(2010)
Safety and Pharmacokinetics of Interathecal Administration of Pemetrexed in the Rat.
Journal of Thoracic Oncology.
대한민국
(2010)
Targeted Therapy-Related Interstitial Lung Disease: A Case-Based Review.
Journal of Thoracic Oncology.
대한민국
(2010)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor.
Journal of Thoracic Oncology.
대한민국
(2010)
Updated Safety and Efficacy Results of a Phase 1/2 Study of PF299804 in Korean Patients with NSCLC Who Experienced Disease Progression on Platinum-Based Chemotherapy Plus Gefitinib or Erlotinib.
Journal of Thoracic Oncology.
대한민국
(2010)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Maintenance for Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Following 1st-Line Platinum-Doublet Chemotherapy.
Annals of Oncology.
이탈리아
(2010)
Molecular profiling of pulmonary plemorphic carcinoma: Implications for targeted treatment of a rare lung malignancy..
Journal of Clinical Oncology.
미국
(2010)
PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib(G): A phase (P) I/II study..
Journal of Clinical Oncology.
대한민국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Clinical Oncology.
미국
(2010)
Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhbitor..
Journal of Clinical Oncology.
미국
